^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL) IN RELAPSED / REFRACTORY CD19+ NON-HODGKIN LYMPHOMA

Published date:
05/11/2023
Excerpt:
The pre-specified overall response rate (ORR) (at day +100) was 73% (95% CI: 58-85%), with a complete response rate (CRR) of 64% (49-78%). Univariate analysis revealed that both histology (indolent vs. aggressive) and serum LDH (normal vs. abnormal) had a significant impact on PFS. Patients with increased LDH had a shorter median PFS compared to those with normal LDH (6.1 months vs not reached, p = 0.006)...High percentage of included patients received var-cel treatment. Var-cel had an acceptable safety profile in adult patients...Long-term persistent absolute BCA was achieved in the majority of patients. In multivariate analysis, only abnormal LDH had a significant impact on PFS.